Company announcementCompany-reported
What was reported
ALAMEDA, Calif., August 6, 2026 (GLOBE NEWSWIRE) – Vivani Medical, Inc. (Nasdaq: VANI) today announced full enrollment and successful initial dosing of all participants in its SLIM-1™ Phase 1 trial for NPM-139, a miniature, subdermal semaglutide implant being designed to provide six- to twelve-months of continuous drug delivery utilizing our proprietary NanoPortal™ technology. The trial of 20 GLP-1 naïve participants in Australia includes low-doses of NPM-139 and Wegovy® to assess safety, tolerability, and pharmacokinetics. Changes in weight will be measured.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Aug 6, 2026 · Open the source ↗
What the evidence supports
Vivani Medical furnished a press release to the SEC (Form 8-K, Item 7.01) about a company announcement. It shows what the company chose to disclose on that date.
What remains unknown
Claims in the release are the company's own and have not been independently verified. Furnishing a document to the SEC does not mean the SEC reviewed or endorsed it.
Source passages
Exact excerpts from the source, with links. Quotes are checked character for character against our stored copy.
Press release headlineVivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight ManagementU.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Aug 6, 2026 · Open the source ↗
Press release lead paragraphALAMEDA, Calif., August 6, 2026 (GLOBE NEWSWIRE) – Vivani Medical, Inc. (Nasdaq: VANI) today announced full enrollment and successful initial dosing of all participants in its SLIM-1™ Phase 1 trial for NPM-139, a miniature, subdermal semaglutide implant being designed to provide six- to twelve-months of continuous drug delivery utilizing our proprietary NanoPortal™ technology. The trial of 20 GLP-1 naïve participants in Australia includes low-doses of NPM-139 and Wegovy® to assess safety, tolerability, and pharmacokinetics. Changes in weight will be measured.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Aug 6, 2026 · Open the source ↗
Revision history
- Revision 1 · Oct 28, 2026, 20:53 UTC
Vivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management
Spotted an error? Tell us. Corrections are published, never silent: see all corrections.